

## 2021:研究業績

1. Abiko K, **Hayashi T**, Yamaguchi K, Mandai M, Konishi I. Potential Novel Ovarian Cancer Treatment Targeting Myeloid Derived Suppressor Cells. **CANCER INVESTIGATION** Published online January 12, 2021. IF 2.4  
Doi: 10.1080/07357907.2020.1871487 <https://www.tandfonline.com/doi/full/10.1080/07357907.2020.1871487>
2. **Hayashi T. Clinical Comment.** In Japan, drinking coffee reduces the risk of colon cancer in women. **JAMA Oncology.** Published online January 05, 2021. (査読有り) (**Hayashi T.** corresponding author). IF 31.8 [Association of Coffee Intake With Survival in Patients With Advanced or Metastatic Colorectal Cancer | Colorectal Cancer | JAMA Oncology | JAMA Network](#)
3. **Hayashi T. Comment.** Advance in cancer genomic medicine as an individualized treatment of cancer. **New Engl J Med. NEJM.** Published online January 05, 2021. (査読有り) (**Hayashi T.** corresponding author). IF 91.2  
[https://www.nejm.org/doi/full/10.1056/NEJMp2030694?query=genetics&page=2#article\\_comments](https://www.nejm.org/doi/full/10.1056/NEJMp2030694?query=genetics&page=2#article_comments)
4. **Hayashi T. Viewpoint:** Effect of SARS-CoV-2 (Y453F) variant on COVID-19 vaccine. **JAMA.** Published on online January 07, 2021. (査読有り) (**Hayashi T.** corresponding author). IF 56.3 [Genetic Variants of SARS-CoV-2—What Do They Mean? | Infectious Diseases | JAMA | JAMA Network](#)
5. **Hayashi T.** Konishi I. **Letter.** Expectations and anxieties about the COVID-19 vaccine in Japan. **Science.** January 09, 2021. (査読有り) (**Hayashi T.** corresponding author). IF 47.7 <https://science.sciencemag.org/content/371/6524/10/tab-e-letters>
6. **Hayashi T.** Konishi I. **Letter.** Japanese government's response to British SARS-CoV-2 mutant. **Science.** January 09, 2021. (査読有り) (**Hayashi T.** corresponding author). IF 47.7 <https://science.sciencemag.org/content/371/6524/9/tab-e-letters>
7. **Hayashi T. Comment.** Priority of COVID-19 vaccination in Japan. **New Engl J Med. NEJM.** Published online January 20, 2021. (査読有り) (**Hayashi T.** corresponding author). IF 91.2  
[https://www.nejm.org/doi/full/10.1056/NEJMp2036128?query=TOC#article\\_comments](https://www.nejm.org/doi/full/10.1056/NEJMp2036128?query=TOC#article_comments)
8. **Hayashi T.** Konishi I. **Letter** Japanese awareness to prevent the spread of SARS-CoV-2N501F variants. **Science.** January 09, 2021. (査読有り) (**Hayashi T.** corresponding author). IF 47.7  
<https://science.sciencemag.org/content/early/2021/01/07/science.abf2946/tab-e-letters>
9. **Hayashi T.** Konishi I. **Letter** In COVID-19 era, impact of restricted movement of people on the seasonal influenza pandemic **Science.** January 17, 2021. (査読有り) (**Hayashi T.** corresponding author). IF 47.7  
<https://science.sciencemag.org/content/371/6526/224/tab-e-letters>
10. **Hayashi T. Clinical Comment.** Effects of platinum preparations on metastatic/recurrent triple-negative breast cancer from clinical trials in Japan. **JAMA Oncology.** Published online January 22, 2021. (査読有り) (**Hayashi T.** corresponding author). IF 31.8  
<https://jamanetwork.com/journals/jamaoncology/fullarticle/2769305>
11. **Hayashi T.** Yaegashi N. Konishi I. **Short Communication.** Effect of RBD Mutation (Y453F) in Spike Glycoprotein of SARS-CoV-2 on Neutralizing Antibody Affinity. **Diagnostic Pathology** 2021. 6(1) 1000181 Published online January 25, 2021. (査読有り) (**Hayashi T.** corresponding author). IF 2.335
12. **Hayashi T. Clinical Comment.** Current status of chemotherapy for uterine sarcoma in Japan. **JAMA Oncology.** 7(3): pp1-2. Published online January 29, 2021. (査読有り) (**Hayashi T.** corresponding author). IF 31.8  
<https://jamanetwork.com/journals/jamaoncology/article-abstract/2775241>
13. **Hayashi T.** Konishi I. **Letter** Effect of RBD (Y453F) in spike glycoprotein of SARS-CoV-2 variant on COVID-19 vaccine. **Science.** January 30, 2021. (査読有り) (**Hayashi T.** corresponding author). IF 47.7  
<https://science.sciencemag.org/content/early/2021/01/22/science.abf9302/tab-e-letters>
14. **Hayashi T. Clinical Comment.** Japan is a reluctant respect to COVID-19 vaccination. **New Engl J Med. NEJM.** Published online January 05, 2021. (査読有り) (**Hayashi T.** corresponding author). IF 91.2  
[https://www.nejm.org/doi/full/10.1056/NEJMp2029466?query=WB#article\\_comments](https://www.nejm.org/doi/full/10.1056/NEJMp2029466?query=WB#article_comments)

15. **Hayashi T.** Amano Y. Ura T. Konishi I. Prospects and Problems of Development of Candidate Vaccine against COVID-19. *International Journal of Trend in Scientific Research and Development (IJTSRD)*. 2021; 5(2): 604-606. (査読有り) (Hayashi T. corresponding author). IF 6.005 <https://www.ijtsrd.com/papers/ijtsrd38521.pdf>
16. **Hayashi T.**, Nobuo Yaegashi, Ikuo Konishi. Effect of RBD (Y453F) mutation in spike glycoprotein of SARS-CoV-2 on neutralizing IgG affinity. *medRxiv Cold Spring Harbor* online published at 2021; 02. 01.  
doi: <https://doi.org/10.1101/2021.01.28.21250577>  
Europe PMC <https://europepmc.org/article/PPR/PPR276425>
17. **Hayashi T. Comment.** Start of Phase 1/2 clinical trial for COVID-19 vaccine (mRNA-1273) in Japan. *New Engl J Med. NEJM*. Published online February 08, 2021. (査読有り) (Hayashi T. corresponding author). IF 91.2  
[https://www.nejm.org/doi/full/10.1056/NEJMoa2035389?query=TOC#article\\_comments](https://www.nejm.org/doi/full/10.1056/NEJMoa2035389?query=TOC#article_comments)
18. **Takuma Hayashi. Clinical Comment.** Treatment policy of COVID-19 with rheumatism drug developed in Japan. *New Engl J Med. NEJM*. Published online February 08, 2021. (査読有り) (Hayashi T. corresponding author). IF 91.2  
[https://www.nejm.org/doi/full/10.1056/NEJMoa2023184?query=TOC#article\\_comments](https://www.nejm.org/doi/full/10.1056/NEJMoa2023184?query=TOC#article_comments)
19. **Hayashi T.** Konishi I. **Letter** Spread of SARS-CoV-2 variants that escape the immune system in Japan *Science*. February 11, 2021. (査読有り) (Hayashi T. corresponding author). IF 47.7  
<https://science.sciencemag.org/content/371/6530/741/tab-e-letters>
20. **Hayashi T. Insight:** Guidelines for COVID-19 vaccination of pregnant women *JAMA*. Published on online February 14, 2021. (査読有り) (Hayashi T. corresponding author). IF 56.3  
<https://jamanetwork.com/journals/jama/fullarticle/2776447>
21. **Hayashi T. Comment.** Treatment status of solid cancer of TMB (10 <) in Japanese cancer genomic medicine. *JAMA Oncology*. Published online February 20, 2021. (査読有り) (Hayashi T. corresponding author). IF 31.8  
<https://jamanetwork.com/journals/jamaoncology/article-abstract/2776411>
22. **Hayashi T.** Konishi I. **Letter** Search of SARS-CoV-2 Mpro inhibitors according to "Supercomputer Fugaku" in Japan *Science*. February 20, 2021. (査読有り) (Hayashi T. corresponding author). IF 47.7  
<https://science.sciencemag.org/content/early/2021/02/17/science.abf1611/tab-e-letters>
23. **Hayashi T. Comment.** Status of cancer medicine by cancer genome profiling in Japan. *JAMA Oncology*. Published online March 03, 2021. (査読有り) (Hayashi T. corresponding author). IF 31.8 [Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors | Genetics and Genomics | JAMA Oncology | JAMA Network](#)
24. **Hayashi T.** Sano K, Ichimura T, Tonegawa S, Yaegashi N, Konishi I. Diagnostic biomarker candidates including NT5DC2 for human uterine mesenchymal tumors. *International Journal of Trend in Scientific Research and Development (IJTSRD)*. 2021; 5(3): 604-606. (査読有り) (Hayashi T. corresponding author). IF 6.005  
<https://www.ijtsrd.com/papers/ijtsrd38686.pdf>
25. **Hayashi T.** Konishi I. Significant decrease in seasonal influenza virus in the COVID-19 era - Impact of global movement restrictions? –*Journal of Clinical Medicine Research (JOCMR)* 2021; 13(3):191-194. Accepted on March 05. 2021 (査読有り) (Hayashi T. corresponding author). IF 2.09 doi: <https://doi.org/10.14740/jocmr4450>
26. **Hayashi T. Clinical Comment.** Current status of olaparib prescription for pancreatic cancer in Japan. *JAMA Oncology*. Published online March 10, 2021. (査読有り) (Hayashi T. corresponding author). IF 31.8  
<https://jamanetwork.com/journals/jamaoncology/article-abstract/2776814>
27. **Hayashi T. Clinical Comment.** Problems with anaphylactic shock after COVID-19 vaccination in Japan. *New Engl J Med. NEJM*. Published online March 10, 2021. (査読有り) (Hayashi T. corresponding author). IF 91.2  
[https://www.nejm.org/doi/full/10.1056/NEJMp2101203?query=TOC#article\\_comments](https://www.nejm.org/doi/full/10.1056/NEJMp2101203?query=TOC#article_comments)
28. **Hayashi T.** Konishi I. **Letter** In Japan, expectance as novel anti-SARS-CoV-2 agent for 5-ALA, an amino acid synthesized in mitochondria. *Science*. March 06, 2021 Vol. 371, Issue 6532, 1-2. (査読有り) (Hayashi T. corresponding author). IF 47.7. <https://science.sciencemag.org/content/371/6532/884/tab-e-letters>

29. **Hayashi T.** Konishi I. **Letter** Importance of tumor neoantigens in the antitumor effect by immune checkpoint inhibitors. *Science*. March 06, 2021 Vol. 371, Issue 6533, pp1-2. (査読有り) (Hayashi T. corresponding author). IF 47.7  
<https://science.sciencemag.org/content/371/6533/1005.5/tab-e-letters>
30. **Hayashi T.** Konishi I. **Letter** In Japan, problems with the development of anaphylactic shock after COVID-19 vaccination. *Science*. March 12, 2021. pp1-2. eabg8663 (査読有り) (Hayashi T. corresponding author). IF 47.7  
<https://science.sciencemag.org/content/early/2021/03/08/science.abg8663/tab-e-letters>
31. Watanabe K, **Hayashi T.** Katsumata M, Sano K, Abiko K, Konishi I. Development of uterine leiomyosarcoma during the follow up after caesarean section in a woman with uterine leiomyoma. *Wufenia journal*. 28(3), pp86-99. 2021. (査読有り) (Hayashi T. corresponding author). IF 1.06  
<http://www.multidisciplinarywufenia.org/auto/index.php/pdf/stream/w22bKeD/1615263102>
32. **Hayashi T.** Konishi I. Non-effect of SARS-CoV-2 spike glycoprotein Y217N mutation on affinity between virus and ACE2 *Journal of Biological Chemistry*. (2021) 296 100725. e1-2. Accepted on March 16, 2021. (査読有り) (Hayashi T. corresponding author). IF 4.238 <https://doi.org/10.1016/j.jbc.2021.100725>
33. **Hayashi T. Comment.** Relationship between coffee drinking, vitamin D intake, aspirin taking and colorectal cancer risk in Japan. *JAMA Oncology*. Published online March 19, 2021. (査読有り) (Hayashi T. corresponding author). IF 31.8  
<https://jamanetwork.com/journals/jamaoncology/fullarticle/2777348>
34. **Hayashi T.** Konishi I. **Letter** Policy on Issuance of Passport for COVID-19 Vaccine by Japanese Government. *Science*. March 18, 2021. Vol. 371, Issue 6535, pp. 1-2. (査読有り) (Hayashi T. corresponding author). IF 47.7  
<https://science.sciencemag.org/content/371/6535/1184/tab-e-letters>
35. **Hayashi T.** Konishi I. Prevalence of anti-SARS-CoV-2 antibody in COVID-19 patients in Japan. *International Journal of Trend in Scientific Research and Development (IJTSRD)*. 2021; 5(3): 375-376. (査読有り) (Hayashi T. corresponding author). IF 6.005 <https://www.ijtsrd.com/papers/ijtsrd39857.pdf>
36. **Hayashi T. Comment.** Current situation of Japan, which was once a vaccine development country. *New Engl J Med. NEJM*. Published online March 20, 2021. (査読有り) (Hayashi T. corresponding author). IF 91.2  
[https://www.nejm.org/doi/full/10.1056/NEJMp2034334?query=WB#article\\_comments](https://www.nejm.org/doi/full/10.1056/NEJMp2034334?query=WB#article_comments)
37. **Hayashi T. Research Letter:** Effect of SARS-CoV-2 subspecies on neutralizing IgG affinity. *JAMA*. Published on online March 30, 2021. (査読有り) (Hayashi T. corresponding author). IF 56.3  
<https://jamanetwork.com/journals/jama/fullarticle/2777898>
38. **Hayashi T.** Yaegashi N. Konishi I. Effect of RBD mutations in spike glycoprotein of SARS-CoV-2 on neutralizing IgG affinity. *Research Square* Published on online March 31, 2021. (査読有り) (Hayashi T. corresponding author).  
<https://www.researchsquare.com/article/rs-363352/v1>  
*medRxiv Cold Spring Harbor*: Published on April 09, 2021 doi: <https://doi.org/10.1101/2021.01.28.21250577>
39. **Hayashi T.** Konishi I. **Letter** Effect of RBD (Y453F) mutation of SARS-CoV-2 on neutralizing IgG affinity. *Science*. March 28, 2021. Vol. 371, Issue 6535, pp. 1-2. (査読有り) (Hayashi T. corresponding author). IF 47.7  
<https://science.sciencemag.org/content/371/6536/1306/tab-e-letters>
40. **Hayashi T. Brief Report** Low prevalence of MSI-High cancer in Japanese patients. *JAMA Oncology*. Published online April 02, 2021. (査読有り) (Hayashi T. corresponding author). IF 31.8  
[https://jamanetwork.com/journals/jamaoncology/fullarticle/2777906?guestAccessKey=615a0ec3-d111-4a9a-9ae5-128e0d491e79&utm\\_source=silverchair&utm\\_medium=email&utm\\_campaign=article\\_alert-jamaoncology&utm\\_content=olf&utm\\_term=040121](https://jamanetwork.com/journals/jamaoncology/fullarticle/2777906?guestAccessKey=615a0ec3-d111-4a9a-9ae5-128e0d491e79&utm_source=silverchair&utm_medium=email&utm_campaign=article_alert-jamaoncology&utm_content=olf&utm_term=040121)
41. **Hayashi T. Perspective** Link between the global movement of people and emerging infectious diseases. *New Engl J Med. NEJM*. Published online April 03, 2021. (査読有り) (Hayashi T. corresponding author). IF 91.2  
[https://www.nejm.org/doi/full/10.1056/NEJMp2034517?query=WB#article\\_comments](https://www.nejm.org/doi/full/10.1056/NEJMp2034517?query=WB#article_comments)
42. **Hayashi T.** Ikuo Konishi. **Research Letter:** Spread of Infection With Tokyo-type SARS-CoV-2 Variant (E484K). *JAMA*. Published on online April 07, 2021. (査読有り) (Hayashi T. corresponding author). IF 56.3  
<https://jamanetwork.com/journals/jama/fullarticle/2776543>

43. **Hayashi T**, Yaegashi N, Konishi I. Effect of RBD mutations in spike glycoprotein of SARS-CoV-2 on neutralizing IgG affinity. *Wulfenia journal*. 28(4), pp106-120. 2021. Published in April. 20, 2021(査読有り) ([Hayashi T](#). corresponding author). IF 1.06 <https://www.multidisciplinarywulfenia.org/auto/index.php/pdf/stream/jXvb7QB/1617526875>
44. **Hayashi T**, Mandai M, Yaegashi N, Konishi I. **Editorial**. New coronavirus disease (COVID-19): Clinical symptoms other than pneumonia with emphasis on thrombosis; *Trends in Immunology and Immunotherapy-TII*. Accepted on April 12, 2021. (査読有り) ([Hayashi T](#). corresponding author). IF NA
45. **Hayashi T**, Konishi I. **Medical News & Perspectives**. Questions: the neutralizing activity against viral mutants by the COVID-19 vaccine? *JAMA* Published on online April 07, 2021. (査読有り) ([Hayashi T](#). corresponding author). IF 56.3 <https://jamanetwork.com/journals/jama/fullarticle/2778876>
46. **Hayashi T**, Konishi I. **Letter** In Tokyo, the situation of the spread of SARS-CoV-2 variants. *Science*. Vol. 372, Issue 6538. pp. 1-2. Published on April 08, 2021. (査読有り) ([Hayashi T](#). corresponding author). IF 47.7 <https://science.sciencemag.org/content/372/6538/eabg3055/tab-e-letters>
47. **Hayashi T**, Konishi I. **Research Comment**. IgA Antibody Against SARS-CoV-2 Variants *JAMA* pp.1. Published on online April 17, 2021. (査読有り) ([Hayashi T](#). corresponding author). IF 56.3 <https://jamanetwork.com/journals/jama/fullarticle/2778766>
48. **Hayashi T**, Konishi I. **Perspective**. Important Relationship between IL-6 Inhibitors and COVID-19 Treatment. *New Engl J Med. NEJM*. 384 pp.1. Published online April 21, 2021. (査読有り) ([Hayashi T](#). corresponding author). IF 91.2 [https://www.nejm.org/doi/full/10.1056/NEJMoa2100433?query=TOC#article\\_comments](https://www.nejm.org/doi/full/10.1056/NEJMoa2100433?query=TOC#article_comments)
49. **Hayashi T**, Konishi I. **Clinical Comment**. Useful clinical information regarding chemotherapy for vulnerable older adult women with ovarian cancer. *JAMA Oncology*. Published online April 25, 2021. (査読有り) ([Hayashi T](#). corresponding author). IF 31.8 [https://jamanetwork.com/journals/jamaoncology/fullarticle/2778657?questAccessKey=03bb6505-e2d5-41f4-b3b0-2ef8c2a4255c&utm\\_source=silverchair&utm\\_medium=email&utm\\_campaign=article\\_alert-jamaoncology&utm\\_term=mostread&utm\\_content=olf-widget\\_04232021](https://jamanetwork.com/journals/jamaoncology/fullarticle/2778657?questAccessKey=03bb6505-e2d5-41f4-b3b0-2ef8c2a4255c&utm_source=silverchair&utm_medium=email&utm_campaign=article_alert-jamaoncology&utm_term=mostread&utm_content=olf-widget_04232021)
50. **Hayashi T**, Konishi I. **Research Comment**. Importance of Establishing Perinatal Management Methods for SARS-CoV-2 infection *JAMA* pp.1. Published on online May 1, 2021. (査読有り) ([Hayashi T](#). corresponding author). IF 56.3 <https://jamanetwork.com/journals/jama/fullarticle/2779586>
51. **Hayashi T**, Konishi I. **Clinical Comment**. Breakthrough treatment for Alzheimer's disease. *New Engl J Med. NEJM*. 2021; 384: pp1. Published online May 06, 2021. (査読有り) ([Hayashi T](#). corresponding author). IF 91.2 [https://www.nejm.org/doi/full/10.1056/NEJMoa2100708?query=TOC#article\\_comments](https://www.nejm.org/doi/full/10.1056/NEJMoa2100708?query=TOC#article_comments)
52. **Hayashi T**, Konishi I. BRCA1/2 alteration in TMB-H as a New Cancer Treatment Option. *JAMA Network Open*. 2021 4(5):e217728 Published online May 09, 2021. (査読有り) ([Hayashi T](#). corresponding author). IF 5.03 <https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2779689>
53. Watanabe K, **Hayashi T**, Katsumata M, Sano K, Abiko K, Konishi I. Development of uterine leiomyosarcoma during the follow up after caesarean section in a woman with uterine leiomyoma. *Anticancer Research*. Published online May 11, 2021. (査読有り) ([Hayashi T](#). corresponding author). IF 1.99 <https://ar.iarjournals.org/content/41/6/3001>
54. **Hayashi T**, Konishi I. **Letter** Viral mutations to make it easier to infect humans in host animals. *Science*. Vol. 372, Issue 6541. pp. 1-2. Published on May 01, 2021. (査読有り) ([Hayashi T](#). corresponding author). IF 47.7 <https://science.sciencemag.org/content/372/6541/466/tab-e-letters>
55. **Hayashi T**, Konishi I. **Letter** Importance of immune activity targeting epitopes in regions other than RBD. *Science*. Vol. 372, Issue 6538. pp. 1-2. Published on May 05, 2021. (査読有り) ([Hayashi T](#). corresponding author). IF 47.7 <https://science.sciencemag.org/content/early/2021/05/03/science.abg5268/tab-e-letters>
56. **Hayashi T**, Yaegashi N, Konishi I. Effect of RBD mutations in spike glycoprotein of SARS-CoV-2 on neutralizing IgG affinity. *medRxiv Cold Spring Harbor*: Published on online May 12, 2021. (査読有り) ([Hayashi T](#). corresponding author). <https://medrxiv.org/cgi/content/short/2021.05.07.21256803v1>

57. **Hayashi T.** Yaegashi N, Konishi I. **Viewpoint.** Need to confirm the safety of COVID-19 vaccination in cancer patients. *JAMA Oncology*. Published online May 16, 2021. (査読有り) (Hayashi T. corresponding author). IF 31.8  
<https://jamanetwork.com/journals/jamaoncology/fullarticle/2780030>
58. **Hayashi T. Comment.** Effects of various vaccinations on B.1.351 variant. *New Engl J Med. NEJM*. 2021; 384, p.1 :Published online May 20, 2021. (査読有り) (Hayashi T. corresponding author). IF 91.2  
[https://www.nejm.org/doi/full/10.1056/NEJMoa2102214?query=TOC#article\\_comments](https://www.nejm.org/doi/full/10.1056/NEJMoa2102214?query=TOC#article_comments)
59. **Hayashi T.** Konishi I. **Letter** In Brazil, importance of COVID-19 vaccination dissemination. *Science*. Vol. 372, Issue 6544. pp. 1-2. Published on May 08, 2021. (査読有り) (Hayashi T. corresponding author). IF 47.7
60. **Hayashi T.** Konishi I. Possibility of SARS-CoV-2 infection in metastatic microenvironment of cancer. *medRxiv Cold Spring Harbor*: Published on online May 27, 2021. (査読有り) (Hayashi T. corresponding author).  
doi: <https://doi.org/10.1101/2021.05.24.21257662>
61. **Hayashi T.** Konishi I. **Viewpoint.** Confirmation of safety of COVID-19 mRNA vaccination for cancer patients. *JAMA Oncology*. Published online May 29, 2021. (査読有り) (Hayashi T. corresponding author). IF 56.3  
<https://jamanetwork.com/journals/jamaoncology/fullarticle/2780584>
62. **Hayashi T. Clinical Comment.** Serious problem with public HIV testing in COVID-19 era. *New Engl J Med. NEJM*. 2021; 384, p.1 :Published online June 03, 2021. (査読有り) (Hayashi T. corresponding author). IF 91.2  
[https://www.nejm.org/doi/full/10.1056/NEJMcp1915826?query=TOC#article\\_comments](https://www.nejm.org/doi/full/10.1056/NEJMcp1915826?query=TOC#article_comments)
63. **Hayashi T.** Konishi I. **Research Comment.** Effect of Second Dose of COVID-19 mRNA Vaccine on Transplant Recipients *JAMA* 2021; 325(21): pp.1. Published on online June 03, 2021. (査読有り) (Hayashi T. corresponding author). IF 56.3. <https://jamanetwork.com/journals/jama/fullarticle/2779852>
64. **Hayashi T.** Sano K, Yaegashi N, Konishi I. Possibility of SARS-CoV-2 infection in metastatic microenvironment of cancer. *Wufenia journal*. Published on online June 03, 2021. (査読有り) (Hayashi T. corresponding author). IF 0.9
65. **Hayashi T.** Konishi I. **Brief Report.** Importance of investigating differences in mutation prevalence between ethnic groups. *JAMA Oncology*. Published online June 06, 2021. (査読有り) (Hayashi T. corresponding author). IF 31.8  
<https://jamanetwork.com/journals/jamaoncology/article-abstract/2780262>
66. **Hayashi T.** Konishi I. **Letter** In Japan, increasing number of students infected with SARS-CoV-2 variants. *Science*. Vol. 372, Issue 6546, pp1-2. Published on June 06, 2021. (査読有り) (Hayashi T. corresponding author). IF 47.7  
<https://science.sciencemag.org/content/372/6546/1092/tab-e-letters>
67. **Hayashi T.** Yaegashi N, Konishi I. Confirmation of safety of COVID-19 mRNA vaccination for cancer patients. *International Journal of Trend in Scientific Research and Development (IJTSRD)*. 2021; 5(4): xxx-xxx. (査読有り) (Hayashi T. corresponding author). IF 6.005 <https://www.ijtsrd.com/papers/ijtsrd42563.pdf>
68. **Hayashi T.** Konishi I. **Clinical Comment.** Importance of developing clinical treatments for platinum-resistant ovarian cancer. *JAMA Oncology*. 2021;7(6): p1-2. Published online June 20, 2021. (査読有り) (Hayashi T. corresponding author). IF 31.8 <https://jamanetwork.com/journals/jamaoncology/article-abstract/2778657>
69. **Hayashi T.** Konishi I. **Viewpoint.** Problems and prospects in cancer genomic medicine in Japan. *JAMA Oncology*. Published online July 03, 2021. (査読有り) (Hayashi T. corresponding author). IF 31.8  
<https://jamanetwork.com/journals/jamaoncology/article-abstract/2781386>
70. **Hayashi T.** Konishi I. **Letter** Gender differences in the frequency of side effects after COVID-19 vaccination in Japan. *Science*. July 09, 2021. Vol. 373, Issue 6551, pp1 (査読有り) (Hayashi T. corresponding author). IF 47.7  
<https://science.sciencemag.org/content/373/6551/145/tab-e-letters>
71. **Hayashi T.** Konishi I. **Clinical Comment.** Guidelines for COVID-19 vaccination for cancer patients in Japan. *JAMA Oncology*. Published online July 10, 2021. (査読有り) (Hayashi T. corresponding author). IF 31.8  
<https://jamanetwork.com/journals/jamaoncology/fullarticle/2781608>

72. **Hayashi T. Comment.** In COVID-19 era, participation in COVAX Facility in Japan. *New Engl J Med. NEJM.* 2021; 384, p.1 :Published online June 03, 2021. (査読有り) (Hayashi T. corresponding author). IF 91.2  
[https://www.nejm.org/doi/full/10.1056/NEJMp2107528?query=WB&cid=NEJM%20Weekend%20Briefing,%20July%2010.%202021%20DM136044\\_NEJM\\_Non\\_Subscriber&bid=543802309#article\\_comments](https://www.nejm.org/doi/full/10.1056/NEJMp2107528?query=WB&cid=NEJM%20Weekend%20Briefing,%20July%2010.%202021%20DM136044_NEJM_Non_Subscriber&bid=543802309#article_comments)
73. **Hayashi T.** Yaegashi N, Tonegawa S, Konishi I. Potential biomarkers associated with malignancy in uterine mesenchymal tumors. *European Journal of Gynaecological Oncology.* 2021, Vol. 42 Issue (5): 824-828  
[DOI: 10.31083/j.ejgo4205125](https://doi.org/10.31083/j.ejgo4205125) (査読有り) (Hayashi T. corresponding author). Accepted on July 20, 2021. IF 1.09
74. **Hayashi T.** Konishi I. **Letter** Importance of anti-SARS-CoV-2 IgA production by COVID-19 vaccination. *Science.* Vol. 373, Issue 6553, pp1-2. Published on July 22, 2021. (査読有り) (Hayashi T. corresponding author). IF 47.7  
<https://science.sciencemag.org/content/373/6553/397/tab-e-letters>
75. **Hayashi T.** Konishi I. **Research Comment:** Effect of COVID-19 vaccine on SARS-CoV-2 variants in age subpopulation. *JAMA.* Published on online July 25, 2021. (査読有り) (Hayashi T. corresponding author). IF 56.3  
<https://jamanetwork.com/journals/jama/fullarticle/2782428>
76. **Hayashi T.** Konishi I. **Comment.** Significance of fractures by treatment with AI for breast cancer. *New Engl J Med. NEJM.* 2021; 385, p.1 :Published online August 02, 2021. (査読有り) (Hayashi T. corresponding author). IF 91.2  
[https://www.nejm.org/doi/full/10.1056/NEJMoa2104162?query=TOC&cid=NEJM%20eToc,%20July%2029,%202021%20A%20DM177921\\_NEJM\\_Non\\_Subscriber&bid=566509722#article\\_comments](https://www.nejm.org/doi/full/10.1056/NEJMoa2104162?query=TOC&cid=NEJM%20eToc,%20July%2029,%202021%20A%20DM177921_NEJM_Non_Subscriber&bid=566509722#article_comments)
77. **Hayashi T.** Konishi I. **Clinical Comment.** In the COVID-19 era, importance of prescribing ACE2-lowering antineoplastics. *JAMA Oncology.* pp.1-2. Published online August 30, 2021. (査読有り) (Hayashi T. corresponding author). IF 31.8  
<https://jamanetwork.com/journals/jamaoncology/fullarticle/2783284>
78. **Hayashi T.** Konishi I. **Letter.** Importance of treatment selection according to SARS-CoV-2 variants. *Science.* Vol. 373, Issue 6555, pp1-2. Published on August 14, 2021. (査読有り) (Hayashi T. corresponding author). IF 47.7  
<https://science.sciencemag.org/content/373/6555/648/tab-e-letters>
79. **Hayashi T.** Konishi I. **Letter.** Identification of host animals susceptible to coronavirus in Japan. *Science.* Vol. 373, Issue 6555, pp1-2. Published on August 17, 2021. (査読有り) (Hayashi T. corresponding author). IF 47.7  
<https://science.sciencemag.org/content/early/2021/08/16/science.abh0117/tab-e-letters>
80. **Hayashi T.** Yaegashi N, Konishi I. **Letter.** Importance of epigenetics-related drug development for advanced/recurrent ovarian cancer *Science.* Vol. 373, Issue 6557, pp1-2. Published on August 21, 2021. (査読有り) (Hayashi T. corresponding author). IF 47.7.  
<https://www.science.org/doi/10.1126/science.acx8917>
81. **Hayashi T.** Konishi I. **Comment.** Importance of IgA secretion by COVID-19 vaccine with inactivated virus. *New Engl J Med. NEJM.* 2021; 385, p.1 :Published online August 01, 2021. (査読有り) (Hayashi T. corresponding author). IF 91.2.  
[https://www.nejm.org/doi/full/10.1056/NEJMoa2107715?query=TOC&cid=NEJM%20eToc,%20September%202,%202021%20DM261172\\_NEJM\\_Non\\_Subscriber&bid=602562240#article\\_comments](https://www.nejm.org/doi/full/10.1056/NEJMoa2107715?query=TOC&cid=NEJM%20eToc,%20September%202,%202021%20DM261172_NEJM_Non_Subscriber&bid=602562240#article_comments)
82. Tamura S. **Hayashi T.** Tokunaga H, Yaegashi N, Abiko K, Konishi I. Oncological Features of Intravenous Leiomyomatosis: Involvement of Mesenchymal Tumor Stem-Like Cells. *Preprints* 2021, 2021090158  
doi: 10.20944/preprints202109.0158.v1. <https://www.preprints.org/manuscript/202109.0158/v1>  
Topic: Cancer Biology and Therapy: *Current Issues in Molecular Biology* 2021, 43(2), 1188-1202;  
(査読有り) (Hayashi T. corresponding author). IF 2.1.  
<https://doi.org/10.3390/cimb43020084>
83. **Hayashi T. Comment.** Advantages and weaknesses of the new type of vaccine. *New Engl J Med. NEJM.* 2021; 385, p.1 :Published online August 01, 2021. (査読有り) (Hayashi T. corresponding author). IF 91.2.  
[https://www.nejm.org/doi/full/10.1056/NEJMp2106970?query=TOC&cid=NEJM%20eToc,%20September%209,%202021%20DM277747\\_NEJM\\_Non\\_Subscriber&bid=607522207#article\\_comments](https://www.nejm.org/doi/full/10.1056/NEJMp2106970?query=TOC&cid=NEJM%20eToc,%20September%209,%202021%20DM277747_NEJM_Non_Subscriber&bid=607522207#article_comments)
84. **Hayashi T.** Konishi I. **Letter.** Inevitability of medical progress for the development of tumor therapy. *Science.* Vol. 374, Issue 6563, pp1-2. Published on October 04, 2021. (査読有り) (Hayashi T. corresponding author). IF 47.7.  
<https://www.science.org/doi/pdf/10.1126/science.abl9080>

85. **Hayashi T.** Konishi I. **Comment.** In Japan, gender difference in the frequency of side effects caused by COVID-19 mRNA vaccination. *JAMA Cardiology*. 2021. 6(10) pp.1-2. Published online October 12, 2021. (査読有り) (Hayashi T. corresponding author). IF 14.7 <https://jamanetwork.com/journals/jamacardiology/fullarticle/2781602>
86. **Hayashi T.** Konishi I. **Clinical Comment.** Onset of Interstitial lung disease in Japanese breast cancer patients treated with T-DXd. *JAMA Oncology*. pp.1-2. Published online October 22, 2021. (査読有り) (Hayashi T. corresponding author). IF 31.8 [https://jamanetwork.com/journals/jamaoncology/fullarticle/2784880?guestAccessKey=8ede6631-d4db-4101-9702-8e5f56a70443&utm\\_source=silverchair&utm\\_medium=email&utm\\_campaign=article\\_alert-jamaoncology&utm\\_term=mostread&utm\\_content=olf-widget\\_10212021](https://jamanetwork.com/journals/jamaoncology/fullarticle/2784880?guestAccessKey=8ede6631-d4db-4101-9702-8e5f56a70443&utm_source=silverchair&utm_medium=email&utm_campaign=article_alert-jamaoncology&utm_term=mostread&utm_content=olf-widget_10212021)
87. **Hayashi T.** Konishi I. **Letter.** In Japan, detection of alpha and delta hybrid type SARS-CoV-2 variants. *Science*. Vol. 374, Issue 6563, pp1-2. Published on October 23, 2021. (査読有り) (Hayashi T. corresponding author). IF 47.7. [https://www.science.org/doi/full/10.1126/science.abj9932?et rid=314888253&utm\\_campaign=fr\\_sci\\_2021-10-21&af=R&et cid=3966952](https://www.science.org/doi/full/10.1126/science.abj9932?et rid=314888253&utm_campaign=fr_sci_2021-10-21&af=R&et cid=3966952)
88. **Hayashi T.** Konishi I. Cancer Therapy With Decreased SARS-CoV-2 Infection Rates in Cancer Patients. *British Journal of Cancer*. Accepted on October 29, 2021. Published online at December 30, 2021. (査読有り) (Hayashi T. corresponding author) IF. 7.64 <https://www.nature.com/articles/s41416-021-01685-3>
89. **Hayashi T.** Sano K, Konishi I. Diagnosis of uterine leiomyosarcoma and leiomyoma after pregnancy with uterine leiomyoma. *Clinical Pathology & Research Journal*. 2021 5(1): 000139. 1-6. Accepted on December 14, 2021. (査読有り) (Hayashi T. corresponding author)
90. **Hayashi T, Konishi I. Comment.** In the COVID-19 era, current status and problems of safety nets in Japan. *New Engl J Med. NEJM*. 2021; 385, p1 Published online December 11, 2021. (査読有り) (Hayashi T. corresponding author). IF 91.2. [https://www.nejm.org/doi/full/10.1056/NEJMp2114010?query=TOC&cid=NEJM%20eToc.%20December%209,%202021%20DM530136\\_NEJM\\_Non\\_Subscriber&bid=731798717](https://www.nejm.org/doi/full/10.1056/NEJMp2114010?query=TOC&cid=NEJM%20eToc.%20December%209,%202021%20DM530136_NEJM_Non_Subscriber&bid=731798717)
91. **Hayashi T. Commet.** Status of the third doses vaccination of COVID-19 mRNA Vaccine (BNT162b2) in Japan. *New Engl J Med. NEJM*. 2021; 385, p1 Published online December 23, 2021. (査読有り) (Hayashi T. corresponding author). IF 91.2. [https://www.nejm.org/doi/full/10.1056/NEJMoa2115624?query=TOC&cid=NEJM%20eToc.%20December%2023,%202021%20DM567993\\_NEJM\\_Non\\_Subscriber&bid=748911375#article\\_comments](https://www.nejm.org/doi/full/10.1056/NEJMoa2115624?query=TOC&cid=NEJM%20eToc.%20December%2023,%202021%20DM567993_NEJM_Non_Subscriber&bid=748911375#article_comments)
92. **Hayashi T.** Konishi I. **Viewpoint Opinion.** Third Dose Vaccination Using mRNA Vaccine (BNT162b2) in Japan. *JAMA* pp.1. Published on online December 25, 2021. (査読有り) (Hayashi T. corresponding author). IF 56.3 [https://jamanetwork.com/journals/jama/fullarticle/2787504?questAccessKey=c10aac66-4be7-4121-9eb2-b7f4f8d427c5&utm\\_source=silverchair&utm\\_medium=email&utm\\_campaign=article\\_alert-jama&utm\\_content=etoc&utm\\_term=122121](https://jamanetwork.com/journals/jama/fullarticle/2787504?questAccessKey=c10aac66-4be7-4121-9eb2-b7f4f8d427c5&utm_source=silverchair&utm_medium=email&utm_campaign=article_alert-jama&utm_content=etoc&utm_term=122121)
93. **Hayashi T.** Konishi I. **Letter.** Expectations for cancer genomic medicine for biliary tract cancer in Japan. *Science* Vol 374, Issue 6573. December 18, 2021. (査読有り) (Hayashi T. corresponding author) IF 47.7. [https://www.science.org/doi/10.1126/science.acx9777?utm\\_campaign=ec\\_sci\\_2021-12-09&et rid=314888253&et cid=4028933](https://www.science.org/doi/10.1126/science.acx9777?utm_campaign=ec_sci_2021-12-09&et rid=314888253&et cid=4028933)

#### 邦文論文

1. 林 琢磨、小西 郁生 子宮間葉性腫瘍に対するリキッドバイオプシーを用いた治療戦略. 研究者の最新動向 65 *Precision Medicine* Vol.4 No.12, 2021 (1061) (林 琢磨 corresponding author) (査読有り)
2. 林 琢磨、小西 郁生. 広範囲の哺乳綱に属する生き物への SARS-CoV-2 の感染拡大の危険と COVID-19 の治療 未病と抗老化. Vol.30, Invited manuscript on April 24 2021. (林 琢磨 corresponding author) (査読有り)
3. 林 琢磨、宇良 敬、小西 郁生. COVID-19 時代、新たな癌治療法の有り方 未病と抗老化. Vol.30, Invited manuscript on April 24 2021. (林 琢磨 corresponding author) (査読有り)
4. 林 琢磨 抗腫瘍剤耐性とエピジェネティックな制御の相関 未病と抗老化. Vol.30, Invited manuscript on April 24 2021. (林 琢磨 corresponding author) (査読有り)

## 国際学会・国際シンポジウム

**招待講演:** [Hayashi T.](#) Ichimura T. Mandai M. Tonegawa S. Yaegasgi N. Konishi I. Molecular Pathology of uterine mesenchymal tumors. **Int'l Conference on Stem Cell Research and Therapy (SCRT 2021). Keynote Speaker. (基調講演)** Location: Grand Link Hotel (桂林桂山华星酒店), **May 29-31, 2021, Guilin, China.**

**招待講演:** [Hayashi T.](#) Ichimura T. Mandai M. Tonegawa S. Yaegasgi N. Konishi I. Molecular Pathology of uterine mesenchymal tumors. **International Conference on Cancer Science: Research & Development (ICSR 2021). June 11-12, 2021. Keynote Speaker. (基調講演)** Prague, Czech Republic.

**依頼講演:** [Hayashi T.](#) Ichimura T. Mandai M. Tonegawa S. Yaegasgi N. Konishi I. Molecular Pathology of uterine mesenchymal tumors for development of diagnosis and clinical therapy. International Conference on Cell Science and Molecular Biology (Cell Science-2021), which will be held during **December 02-04, 2021. in Rome, Italy.**

**招待講演:** [Hayashi T.](#) Ichimura T. Mandai M. Tonegawa S. Yaegasgi N. Konishi I. Molecular Pathology of uterine mesenchymal tumors for development of diagnosis and clinical therapy. **Biotechnology and Genetics World Forum** to be held during **November 04-06, 2021 in Edinburgh, Scotland.**

**招待講演:** [Hayashi T.](#) Ura T, Amano Y, Mandan M, Yaegashi N, Konishi I. Zoonotic disease: A highly conserved binding region of ACE2 as receptor for SARS-CoV-2 between human and mammals. **Experts Meet on Infectious Diseases & Research conference 18-19 October 2021 at Rome, Italy**

**招待講演:** [Hayashi T.](#) Mandai M. Yaegasgi Y. Konishi I. Significant Decrease in Seasonal Influenza in the COVID-19 Era: Impact of Global Movement Restrictions? **5<sup>th</sup> International Conference on Virology and Infectious Diseases** scheduled during **September 16-17, 2021 in Paris, France.**

**招待講演:** [Hayashi T.](#) Konishi I. Possibility of SARS-CoV-2 infection in metastatic microenvironment of cancer. **International Society for Infectious Diseases 2021 November 4-6, 2021 in Brookline, MA USA**

Tamura S. [Hayashi T.](#) Tokunaga H. Yaegashi N. Abiko K. Konishi I. Oncological Features of Intravenous Leiomyomatosis: Involvement of Mesenchymal Tumor Stem-Like Cells. **Overcoming Therapy Resistance in Cancer Cell Symposia November 9, 2021. Cambridge, MA, USA**

**招待講演:** [Hayashi T.](#) Yaegashi N, Konishi I. Highly conserved binding region of ACE2 as a receptor for SARS-CoV-2 between humans and mammals. **International E-Conference on COVID-19 Pandemic** going to be held on **December 14-15, 2021. London, United Kingdom. Keynote Speaker. (基調講演)**

**天野 泰彰、林 琢磨、安彦 郁、万代 昌紀、八重樫 伸生、小西 郁生.** クリニカルシークエンスの今後の展望：婦人科腫瘍におけるがんゲノム医療の新たな展開。一般口演 第63回日本婦人科腫瘍学会 2021年7月16日 大阪、日本

**林 琢磨、佐野 健司、市村 友季、Dorit Zharhary、利根川 進、油田 浩幸、金井 弥栄、八重樫 伸生、小西 郁生.** クリニカルシークエンスの医療：婦人科腫瘍におけるがんゲノム医療の新たな展開。第73回日本産科婦人科学会学術講演会 2021年4月22日(木)～25日(日) 新潟、日本

**Hayashi T. International Session.** Study of early diagnosis and treatment for platinum-resistant recurrent/advanced ovarian cancer. 日本人類遺伝学会第66回大会 第28回日本遺伝子診療学会大会. 2021年10月16日 横浜、日本

**林 琢磨** 「新型コロナウイルス感染症の最前線-what is known and unknown #1」 「新型コロナウイルスワクチンと感染メカニズム」 **内閣府/日本学術会議主催の学術フォーラム** 5月8日 2021年 東京

## 受賞

**林 琢磨、安彦 郁、山口 建、山田 亮、松村 謙臣、万代 昌紀、小西 郁生.** プラチナ製剤抵抗性再発・進行性卵巣がんに対する早期診断と治療法の検討。第63回日本婦人科腫瘍学会 2021年7月16日 **優秀演題賞(高得点演題)** 大阪

**林 琢磨、小西 郁生.** 広範囲の哺乳綱に属する生き物への SARS-CoV-2 の感染拡大の危惧と COVID-19 の治療 未病と抗老化. 一般財団法人博慈会 老人研究所の2021年度 **優秀論文賞**

## マスメディア・報道

林 琢磨：聞き手 遠山嘉之：ワクチン2回接種の高齢者にコロナ感染が増えている理由 専門家に聞いた **日刊現代** 09.05.2021  
**Yahoo ニュース Life** ([Yahoo トップページに掲載](#))  
<https://news.yahoo.co.jp/articles/bcf3584b671039a6aaeeefb57e43ccc9dfc3369a>  
ワクチン2回接種の高齢者にコロナ感染が増えている理由 専門家に聞いた (日刊ゲンダイ DIGITAL) - Yahoo!ニュース  
<https://www.nikkan-gendai.com/articles/view/life/294329>  
<https://ktnoksn.hatenablog.com/entry/2021/09/06/163719>

林 琢磨：聞き手 遠山嘉之：遺伝子書き換え、不妊…新型コロナのワクチン接種をめぐる「デマ」と「事実」を専門家に聞いた **日刊現代** 09.24.2021  
**Yahoo ニュース Life** ([Yahoo トップページに掲載](#))  
<https://news.yahoo.co.jp/articles/aee8501b98facad88db818cf8ad5d1e07b6029cf>  
遺伝子書き換え、不妊…新型コロナのワクチン接種をめぐる「デマ」と「事実」を専門家に聞いた (日刊ゲンダイ DIGITAL) - Yahoo!ニュース  
<https://www.nikkan-gendai.com/articles/view/life/295111>

林 琢磨：聞き手 遠山嘉之：重感染、スーパー感染…新型コロナに続くインフルエンザ流行の備えはどこまで? **日刊現代** 10.16.2021  
**Yahoo ニュース Life** ([Yahoo トップページに掲載](#))  
<https://news.yahoo.co.jp/articles/4dd32c898fa35b0278ae1c4dbf815375287776cc>  
重感染、スーパー感染…新型コロナに続くインフルエンザ流行の備えはどこまで? (日刊ゲンダイ DIGITAL) - Yahoo!ニュース  
<https://www.nikkan-gendai.com/articles/view/life/296090>  
<https://topics.smt.docomo.ne.jp/article/nikkangendai/life/nikkangendai-774829>

## 教育業績

**Harvard Medical School** ハーバード大学医学部：[Advanced Teaching Skills](#) program  
**Time:** June 05, 2021. Boston MA, USA.

**Harvard Medical School** ハーバード大学医学部：[Global Clinical Scholars Research Training \(GCSRT\)](#) program  
Enhance Your Clinical Research Skills. Personalize Your Academic Focus. Learn with **Harvard Medical School**.  
**Time:** June 11-15, 2021. Boston MA, USA.

**Harvard Medical School** ハーバード大学医学部：[Cancer Genomics and Precision Oncology](#)  
**Courses are led by Harvard Medical School faculty**  
HMX Pro Genetics Cancer Genomics and Precision Oncology  
**Time:** August 03, 2021. Boston MA, USA.

医学教育サイバーシンポジウム 2021: COVID-19 パンデミック 2 年目の医学教育  
「コロナ禍でどのように医学教育を進めていくか」 医学教育サイバーシンポジウム事務局 5月29日 2021年

## Editor

The International Journal of Molecular Sciences (ISSN 1422-0067, IF 4.556)  
Current Gene Therapy (CGT) (ISSN: 1566-5232, IF 2.431)

## 研究費

林 琢磨 プラチナ製剤抵抗性再発・進行性卵巣がんに対する早期診断と治療法の検討 (20万円) 2021年度 協和キリン株式会社 研究サポート寄附プログラム